The approved share increases and warrant issuance authorization enable significant future dilution without any near-term catalyst. Monitor for the actual filing of the Charter Amendment and any subsequent equity issuances or warrant exercises, which would further pressure the stock. The narrow vote margin on the plan increase (52% For of votes cast) suggests notable retail/insider opposition.
TOVX drugs
TOVX drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $0.2300entry
- T+1 · 3mo ago −2.13%α −1.93% · $0.2251
- T+5 · 3mo ago 0.00%α +0.10% · $0.2300
- T+20 · 3mo ago +8.26%α +9.50% · $0.2490
- T+60 · 20d ago −17.39%α −17.77% · $0.1900
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all six proposals, including an amendment to increase the 2020 Stock Incentive Plan share pool from 4,500,000 to 6,500,000 shares, an increase in authorized common shares, and the issuance of common stock upon warrant exercise. The filing is a routine post-meeting report with no financial results or material corporate events, the increased share authorization and warrant issuance approval signal potential future dilution, but no immediate action has been taken. For a $10M market cap micro-cap, the approval of a 44% increase in the equity incentive pool and a broad authorized share increase is a modestly bearish signal for existing holders, as it enables future dilution without any current operational catalyst to offset it.
Key Facts
- Stockholders approved Amendment No. 4 to the 2020 Stock Incentive Plan, increasing the share pool from 4,500,000 to 6,500,000 shares (a 44% increase).
- Stockholders approved an amendment to increase the number of authorized shares of common stock (Charter Amendment), though the Board retains discretion not to file it.
- Stockholders approved the issuance of common stock upon exercise of outstanding warrants.
- All four director nominees (Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, Jeffrey Wolf) were re-elected.
- BDO USA, P.C. was ratified as independent auditor for FY 2026.
- Proposal 3 (plan increase) passed narrowly: 3,110,068 For vs 2,840,658 Against, with 10,823,826 broker non-votes.
- Proposal 5 (warrant exercise shares) passed: 3,665,312 For vs 2,267,592 Against, with 10,823,826 broker non-votes.
Financial Impact
Equity incentive pool increased by 2,000,000 shares (44% expansion). Authorized share count increase approved but not yet filed. Warrant exercise shares approved, potential dilution from outstanding warrants.
Risk Factors
- Potential dilution from the 2,000,000 additional shares authorized under the stock plan
- Potential dilution from warrant exercises (Proposal 5 approval)
- Possible future authorized share increase filing by Board discretion
- Narrow approval margins indicate shareholder pushback on dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-090064 |
| Document: tm2619846d1_ex10-1.htm | 0001104659-26-090064 |
| Document: 0001104659-26-090064-index-headers.html | 0001104659-26-090064 |
| Document: 0001104659-26-090064-index.html | 0001104659-26-090064 |
| Document: 0001104659-26-090064.txt | 0001104659-26-090064 |
Track record
11 reports on TOVX
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +4.37% at T+5 after the Oct 20, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
- Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
- Aug 4, 202614w ago 8-K Bearish 4/10 Viewing Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
- Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
- Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
- Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers